

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	NA	NA	X	NA	X	X	NA

## Mavyret (glecaprevir/pibrentasvir)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	Based on Genotype, Treatment status, Cirrhosis status, or Transplant status.

Medication	Quantity Limit
Mavyret (glecaprevir/pibrentasvir)	3 tablets per day

### APPROVAL DURATION

Genotype and Status (HCV mono-infected or HCV/HIV-1 co-infected <sup>a</sup> )	Associated Treatment Regimens	Total Approval Duration of Mavyret
Genotypes 1, 2, 3, 4, 5, or 6 (treatment-naïve, with compensated cirrhosis or without cirrhosis)	Mavyret	8 weeks
Genotypes 1, 2, 3, 4, 5, or 6, or Genotype unknown (acute HCV, treatment-naïve, without cirrhosis)	Mavyret	8 weeks
Genotypes 1, 2, 3, 4, 5, or 6 (treatment failure with Mavyret monotherapy, with compensated cirrhosis or without cirrhosis)	Mavyret + Sovaldi + RBV	16 weeks
Genotype 1 (treatment-experienced with an NS5A <sup>2a</sup> inhibitor and without prior treatment with an NS3/4A <sup>2c</sup> protease inhibitor, with compensated cirrhosis or without cirrhosis)	Mavyret	16 weeks
Genotype 1 (treatment-experienced with an NS3/4A <sup>2c</sup> protease inhibitor or sofosbuvir and without prior treatment with an NS5A <sup>2a</sup> inhibitor, with compensated cirrhosis or without cirrhosis)	Mavyret	12 weeks

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	NA	NA	X	NA	X	X	NA

Genotype 2 (treatment-experienced with sofosbuvir + ribavirin, with compensated cirrhosis or without cirrhosis)	Mavyret	12 weeks
Genotype 2 (dual P/R <sup>2b</sup> treatment-experienced, without cirrhosis)	Mavyret	8 weeks
Genotype 2 (dual P/R <sup>2b</sup> treatment-experienced, with compensated cirrhosis)	Mavyret	12 weeks
Genotype 3 (dual P/R <sup>2b</sup> treatment-experienced, or experienced with sofosbuvir-containing regimen, without NS3/4A <sup>2c</sup> or NS5A <sup>2a</sup> , with compensated cirrhosis or without cirrhosis)	Mavyret	16 weeks
Genotypes 1, 4, 5, or 6 (dual P/R <sup>2b</sup> treatment-experienced, or experienced with sofosbuvir-containing regimen, without NS3/4A <sup>2c</sup> or NS5A <sup>2a</sup> , without cirrhosis)	Mavyret	8 weeks
Genotypes 1, 4, 5, and 6 (dual P/R <sup>2b</sup> treatment-experienced, or experienced with sofosbuvir-containing regimen, without NS3/4 <sup>2c</sup> or NS5A <sup>2a</sup> with compensated cirrhosis)	Mavyret	12 weeks
Genotypes 1, 2, 3, 4, 5, or 6 (treatment-naïve or treatment-experienced, post-liver allograft transplant recipient, with compensated cirrhosis or without cirrhosis)	Mavyret	12 weeks
Genotypes 1, 2, 3, 4, 5, or 6 (treatment-naïve or treatment-experienced, post-kidney transplant recipient, with compensated cirrhosis or without cirrhosis)	Mavyret	12 weeks

## **APPROVAL CRITERIA**

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	NA	NA	X	NA	X	X	NA

Requests for Mavyret (glecaprevir/pibrentasvir) may be approved if the following criteria are met:

- I. Individual is 12 years of age or older **or** weighing at least 45 kg; **AND**
- II. Documentation is provided for a diagnosis of chronic hepatitis C (CHC) infection<sup>a</sup>, which includes genotype and a positive HCV RNA result (AASLD/IDSA 2017, CDC 2013); **AND**
- III. Individual has received baseline evaluation for liver fibrosis to guide appropriate therapy; **AND**
- IV. Individual does not have a short life expectancy (less than 12 months owing to non-liver related comorbid conditions) that cannot be remediated by treating HCV, by transplantation or other directed therapy (AASLD/IDSA 2017); **AND**
- V. Individual has compensated<sup>1</sup> liver disease (with or without cirrhosis);

**AND**

- VI. Individual is using in **one** of the following antiviral treatment regimens (Label/AASLD/IDSA 2019):
  - A. As monotherapy for **one** of the following:
    1. Individual is treatment-naïve, with compensated<sup>1</sup> cirrhosis or without cirrhosis, and Genotypes 1, 2, 3, 4, 5, or 6;

**OR**

  - 2. Individual is treatment-experienced with a prior HCV NS5A<sup>2a</sup> inhibitor regimen without prior HCV treatment with an NS3/4A<sup>2c</sup> protease inhibitor with compensated<sup>1</sup> cirrhosis or without cirrhosis, and Genotype 1;

**OR**

  - 3. Individual is treatment-experienced with a prior HCV NS3/4A<sup>2c</sup> protease inhibitor regimen without prior HCV treatment with an NS5A<sup>2a</sup> inhibitor, with compensated<sup>1</sup> cirrhosis or without cirrhosis, and Genotype 1;

**OR**

  - 4. Individual is dual P/R<sup>2b</sup> treatment-experience, or experienced with sofosbuvir-containing regimen, without NS3/4A<sup>2c</sup> or NS5A<sup>2a</sup>, with compensated cirrhosis or without cirrhosis, and Genotypes 1, 2, 3, 4, 5, or 6;

**OR**

  - 5. Individual is a post-liver allograft transplant recipient with or without compensated<sup>1</sup> cirrhosis, and Genotypes 1, 2, 3, 4, 5, or 6;

**OR**

  - 6. Individual is a post-kidney transplant recipient, with or without compensated<sup>1</sup> cirrhosis, and Genotypes 1, 2, 3, 4, 5, or 6;

**OR**

- B. In combination with Sovaldi (sofosbuvir) and ribavirin for the following (AASLD/IDSA 2019):
  1. Individual had prior treatment failure with Mavyret (glecaprevir/pibrentasvir)

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	NA	NA	X	NA	X	X	NA

monotherapy; **AND**

2. Individual has Genotype 1, 2, 3, 4, 5, or 6, with compensated cirrhosis or without cirrhosis;

**OR**

- VII. Individual is 12 years of age or older **or** weighing at least 45 kg, and meets all of the following (AASLD/IDSA 2019):
  - A. Documentation is provided for a diagnosis of acute hepatitis C infection<sup>a</sup>, which includes a positive HCV RNA result, and with or without genotype; **AND**
  - B. Individual has received baseline evaluation for liver fibrosis to guide appropriate therapy; **AND**
  - C. Individual does not have a short life expectancy (less than 12 months owing to non-liver related comorbid conditions) that cannot be remediated by treating HCV, by transplantation or other directed therapy; **AND**
  - D. Individual is treatment-naïve, without cirrhosis, and Genotype 1, 2, 3, 4, 5, or 6, or genotype is unknown.

Mavyret (glecaprevir/pibrentasvir) may **not** be approved for the following:

- I. Individual has decompensated<sup>1</sup> cirrhosis, or any history of prior hepatic decompensation; **OR**
- II. Individual is requesting in concurrent therapy with contraindicated or not recommended agents, including but not limited to ritonavir-containing antiretroviral regimens, efavirenz, etravirine, nevirapine, darunavir/cobicistat, atazanavir, carbamazepine, St John's wort, ethinyl estradiol-containing medications, atorvastatin, lovastatin, simvastatin, and rifampin; **OR**
- III. Individual is using in combination with a regimen containing a non-nucleoside NS5B polymerase inhibitor (such as dasabuvir) ; **OR**
- IV. Individual is using in combination with a regimen containing another NS5A<sup>2a</sup> inhibitor; **OR**
- V. Individual is using in combination with a regimen containing another NS3/4A<sup>2c</sup> protease inhibitor; **OR**
- VI. Individual is requesting the regimen for re-treatment and either failed to achieve a SVR (defined as a lower limit HCV RNA of 25 IU/mL) or relapsed after achieving a SVR during a prior successfully completed treatment regimen consisting of elbasvir/grazoprevir, ombitasvir/paritaprevir/ritonavir and dasabuvir, ombitasvir/paritaprevir/ritonavir, or sofosbuvir/velpatasvir/voxilaprevir.

**Notes:**

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	NA	NA	X	NA	X	X	NA

<sup>a</sup>Per label and AASLD/IDSA treatment guidance, Mavyret (glecaprevir/pibrentasvir) may be used in individuals who are co-infected with HIV-1.

### 1. **Compensated Liver Disease:**

According to the American Association for the Study of Liver Diseases (AASLD/IDSA2017), the specific criteria for compensated liver disease include all of the following: a total bilirubin; serum albumin; prothrombin time/INR; presence of ascites; and presence of hepatic encephalopathy. However, these criteria do not establish a comprehensive definition of compensated liver disease. The AASLD guidance refers to compensated liver disease as Class A based on the Child Pugh-Turcotte (CPT) classification scoring system.

Moderate to Severe (Decompensated) Liver Disease:

The AASLD guidance refers to decompensated (moderate to severe) liver disease as Class B or C based on the Child-Pugh Turcotte (CPT) classification scoring system.

### **Child Pugh Classification (AASLD/IDSA 2017)**

Parameters			
Points Assigned	1 point	2 points	3 points
Total Bilirubin (µmol/L)	<34	34-50	>50
Serum Albumin (g/L)	>35	28-35	<28
Prothrombin time/INR	<1.7	1.71-2.30	>2.30
Ascites	None	Mild	Moderate to Severe
Hepatic Encephalopathy	None	Grade I-II (or suppressed with medication)	Grade III-IV (or refractory)

### **Child Pugh Score Interpretation (AASLD/IDSA 2017)**

Class A	5-6 points	Well compensated liver disease
Class B	7-9 points	Significant functional compromise (moderate hepatic impairment)
Class C	10-15 points	Uncompensated liver disease (severe hepatic impairment)

### 2. Past Treatment Exposure Definitions (AASLD/IDSA 2017):

- a. NS5A Inhibitor: includes daclatasvir, ledipasvir, elbasvir, ombitasvir, pibrentasvir, or velpatasvir-containing regimens
- b. P/R: includes peginterferon (or non-pegylated interferon) ± ribavirin
- c. NS3/4A Protease Inhibitor: includes simeprevir, grazoprevir, paritaprevir, glecaprevir, and voxilaprevir-containing regimens
- d. Triple therapy: includes NS3 protease inhibitor (simeprevir, boceprevir or telaprevir) plus peginterferon and ribavirin

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	NA	NA	X	NA	X	X	NA

- e. Direct Acting Antiviral (DAA): includes NS5A inhibitors, NS3/4A protease inhibitors, and NS5B polymerase inhibitors (sofosbuvir, dasabuvir)

3. Chronic Kidney Disease (CKD) Definitions (AASLD/IDSA 2017):

Severe CKD (Stage 4): eGFR 15-29 mL/min

End-Stage CKD (Stage 5): eGFR < 15 mL/min

4. Metavir Scoring Systems for Fibrosis Staging (AASLD 2009):

Stage (F)	
0	No fibrosis
1	Periportal fibrotic expansion
2	Periportal septae 1 (septum)
3	Porto-central septae
4	Cirrhosis

5. Hepatitis C virus (HCV) direct acting antiviral (DAA) agents have a black box warning for risk of hepatitis B virus (HBV) reactivation in individuals with HCV-HBV co-infection. Individuals should be tested for evidence of current or prior HBV infection prior to initiation of DAA therapy. HBV reactivation has been reported in HCV/HBV co-infected individuals currently taking or previously completed DAA therapy and not concomitantly receiving HBV antiviral therapy. Some cases of HBV reactivation have led to fulminant hepatitis, hepatic failure, and death. Individuals should be monitored for hepatitis flare or HBV reactivation during and following HCV DAA therapy. Individuals should be appropriately managed for HBV infection as indicated.

**Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 13, 2020.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
5. American Association for the Study of Liver Diseases and the Infectious Disease Society of America, in collaboration with the International Antiviral Society-USA. Recommendations for testing, managing and treating hepatitis C. Available at <http://www.hcvguidelines.org/>. Published on: January 29, 2014. Updated on: November 6, 2019. Accessed on: January 13, 2020
6. Centers for Disease Control and Prevention. Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians. *MMWR*. 2013; 62(18):362-365. Available from: <https://www.cdc.gov/mmwr/pdf/wk/mm6218.pdf>. Accessed on: January 13, 2020.
7. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. *J Hepatol*. 2018; <https://doi.org/10.1016/j.jhep.2018.03.026>. Available from: <http://www.easl.eu/research/our-contributions/clinical-practiceguidelines/detail/easl-recommendations-on-treatment-of-hepatitis-c-2018>. Accessed on: January 13, 2020.
8. Kamal SM. Acute hepatitis C: a systematic review. *Am J Gastroenterol*. 2008;103(5):1283-1297.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	NA	NA	X	NA	X	X	NA

9. U.S. Department of Health and Human Services AIDSinfo treatment guidelines. Considerations for Antiretroviral Use in Patients with Coinfections. Available at <https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/26/hcv-hiv>. Accessed on: January 13, 2020.
10. Wyles D, Weiland O, Yao B, et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019;70(5):1019-1023.